Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORY-OSA phase 3 trial of IBI362 in obesity-related moderate-to-severe obstructive sleep apnea
CTR20251394Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Jun 2025
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity, sponsored by InnoCare Pharma. Started Jun 2025; status: active.
02
Drugs
mazdutide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on CTR20251394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251394.